Jin, Jie
Zhang, Lei
Qin, Albert
Wu, Daoxiang
Shao, Zonghong
Bai, Jie
Chen, Suning
Duan, Minghui
Zhou, Hu
Xu, Na
Zhang, Sujiang
Zuo, Xuelan
Du, Xin
Wang, Li
Li, Pei
Zhang, Xuhan
Li, Yaning
Zhang, Jingjing
Wang, Wei
Shen, Weihong
Zagrijtschuk, Oleh
Urbanski, Raymond
Sato, Toshiaki
Xiao, Zhijian
Clinical trials referenced in this document:
Documents that mention this clinical trial
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera
https://doi.org/10.1186/s40164-023-00415-0
Funding for this research was provided by:
PharmaEssentia Corporation
Article History
Received: 29 March 2023
Accepted: 16 May 2023
First Online: 21 June 2023
Declarations
:
: The study was approved by the ethics committee or appropriate institutional review board of all the participating hospitals and clinical centers and followed the principles of the Declaration of Helsinki for all human experimental investigations. Informed consent was obtained from all patients participating in this study.
: Not applicable.
: JJ, LZ, ZS, JBi, SC, MD, HZ, NX, SZ, XZ, XD, LW, PL, XZ, and ZX have no competing of interests to disclose. AQ, OZ, RU, TS are employees of PharmaEssentia Corporation. DW, WS, WW, JZ, and Yi are employees of PharmaEssentia Biotech (Beijing) Ltd.